iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference



    VANCOUVER, Feb. 19 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to announce that early results for iCo's Diabetic Macular Edema (DME)
candidate, iCo-007, will be highlighted in a presentation at a prominent
ocular conference.
    The presentation will be given by Geeta A. Lalwani, MD, Assistant
Professor of Clinical Ophthalmology, Vitreoretinal Diseases and Surgery at the
Bascom Palmer Eye Institute University of Miami Miller School of Medicine. The
Bascom Palmer Eye Institute is one of the premier eye centres in the world,
and one of the four U.S. sites conducting iCo's ongoing iCo-007 clinical
trial. Along with Philip Rosenfeld, MD, Dr. Lalwani is an investigator
participating in the Phase I clinical trial in DME patients. The primary
endpoint of the open label, dose escalating trial is safety, with visual
acuity and measures of retinal thickness serving as secondary endpoints.
    The conference, "Angiogenesis, Exudation and Degeneration 2009", will be
held on Saturday, February 21, 2009 at the Ritz-Carlton Key Biscayne. The
conference will feature prominent scientists, clinicians and healthcare
experts in neovascular diseases of the eye, including AMD and DME. Dr.
Lalwani's presentation will be held at 4:25pm.

    About iCo-007

    iCo-007 is expected to decrease swelling in the retina and related visual
impairment by decreasing the signaling of multiple growth factors, including
VEGF, IGF, bFGF, EPO and HGF that signal through the c-Raf kinase/MAP kinase
pathway. iCo-007 may also be a potential treatment for certain oncology
indications, as c-Raf kinase is the predominant Raf isoform responsible for
regulating cellular growth in ovarian cancer. iCo-007 is an antisense drug
discovered by Isis Pharmaceuticals, Inc. (Nasdaq:   ISIS) and licensed to iCo
Therapeutics for the treatment of various eye diseases.

    About iCo Therapeutics

    iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on
redosing or reformulating drugs with clinical history for new or expanded
indications. iCo has exclusive worldwide rights to three products, iCo-007, in
Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with
Phase II clinical history to be developed for severe ocular allergies, and
iCo-009, an oral formulation of Amphotericin B for sight and life -
threatening diseases. iCo-009 also represents a new drug delivery technology
with the potential to reprofile other parenteral administered drugs to the
oral route of administration. iCo Therapeutics trades on the TSX-Venture
exchange under the symbol "ICO". For more information, visit the company
website at: www.icotherapeutics.com

    
    No regulatory authority has approved or disapproved the content of this
    release. The TSX Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release.
    

    Forward Looking Statements

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on iCo
Therapeutics' current beliefs as well as assumptions made by and information
currently available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo Therapeutics in its
public securities filings; actual events may differ materially from current
expectations. iCo Therapeutics disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

    %SEDAR: 00024061E




For further information:

For further information: Business Development: Dr. John Clement, CBO,
(778) 688-0644; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414 x 224;
Investor/Media Contact: Frederica Bell, Corp. Devt., (604) 602-9414 x 228; B&D
Capital, Joanne Calverley, (604) 685-6465

Organization Profile

iCo Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890